Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System
- Authors
- Tomasetti, Carmine; Montemitro, Chiara; Fiengo, Annastasia L. C.; Santone, Cristina; Orsolini, Laura; Valchera, Alessandro; Carano, Alessandro; Pompili, Maurizio; Serafini, Gianluca; Perna, Giampaolo; Vellante, Federica; Martinotti, Giovanni; Giannantonio, Massimo D.; Kim, Yong-Ku; Nicola, Marco D.; Bellomo, Antonello; Ventriglio, Antonio; Fornaro, Michele; Berardis, Domenico D.
- Issue Date
- 2019
- Publisher
- BENTHAM SCIENCE PUBL LTD
- Keywords
- Depressive disorders; glutamate; postsynaptic density; antipsychotics; antidepressants; NMDA; ketamine; mGluR
- Citation
- CURRENT PHARMACEUTICAL DESIGN, v.25, no.4, pp.381 - 387
- Indexed
- SCIE
SCOPUS
- Journal Title
- CURRENT PHARMACEUTICAL DESIGN
- Volume
- 25
- Number
- 4
- Start Page
- 381
- End Page
- 387
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/68897
- DOI
- 10.2174/1381612825666190312102444
- ISSN
- 1381-6128
- Abstract
- Depressive disorders represent protean psychiatric illnesses with heterogeneous clinical manifestations and a multitude of comorbidities leading to severe disability. In spite of decades of research on the pathophysiogenesis of these disorders, the wide variety of pharmacotherapies currently used to treat them is based on the modulation of monoamines, whose alteration has been considered the neurobiological foundation of depression, and consequently of its treatment. However, approximately one third to a half of patients respond partially or become refractory to monoamine-based therapies, thereby jeopardizing the therapeutic effectiveness in the real world of clinical practice. Recent scientific evidence has been pointing out the essential role of other biological systems beyond monoamines in the pathophysiology of depressive disorders, in particular, the glutamatergic neurotransmission. In the present review, we will discuss the most advanced knowledge on the involvement of glutamatergic system in the molecular mechanisms at the basis of depression pathophysiology, as well as the glutamate-based therapeutic strategies currently suggested to optimize depression treatment (e.g., ketamine). Finally, we will mention further "neurobiological targeted" approaches, based on glutamate system, with the purpose of promoting new avenues of investigation aiming at developing interventions that overstep the monoaminergic boundaries to improve depressive disorders therapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.